- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06237205
Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency
Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency (GAUSS)
Study Overview
Detailed Description
Objectives:
Primary Objective
- Antitumor activity defined as objective response at ≥ 8 weeks or stable disease (SD) at ≥ 16 weeks from the time of enrollment.
Secondary Objectives
- Overall Survival (OS)
- Progression-Free Survival (PFS)
- Objective Response Rate (ORR) by RECIST v1.1
- Duration of response (DOR)
- Quality of life (QOL) assessed by EORTC-QLQ-C30
- Adverse Event (AEs)
- Exploratory biomarker analyses
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: soohyeon lee, phd
- Phone Number: +82-2-920-6078 +82-2-920-6078
- Email: soohyeon_lee@korea.ac.kr
Study Contact Backup
- Name: chanju park, bs
- Phone Number: +82-2-920-6078 +82-2-920-6078
- Email: ckswn4869@kumc.or.kr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient who agreed to participate in the KOSMOS-II master observation study.
- 19 years of age or older on the day of signing informed consent.
- Has a histologically- or cytologically-confirmed advanced (metastatic and/or unresectable) solid tumor.
- Has either known or suspected deleterious mutations in at least 1 of the genes involved in HRR or centrally confirmed HRD based on whole-genome sequencing (WGS).
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Has measurable disease per RECIST v1.1 as assessed by the local site investigator.
- Female participants of reproductive potential must agree to use contraception during the treatment period and for at least 6 months after the last dose. Male participants must agree to use contraception during the treatment period and for 90 days plus 5 X half-life after last dose.
- Has adequate organ function.
- Willing to provide biopsies from the tumor at screening to the central laboratory
Exclusion Criteria:
- Any previous exposure to PARP inhibitor
- Any other active malignancy or diagnosis of another malignancy within 2 years before study enrollment
- Has leptomeningeal metastases.
- Active central nervous system (CNS) lesions.
- Were resistant to prior platinum therapy (cisplatin, carboplatin, or oxaliplatin either as monotherapy or in combination) for advanced (metastatic and/or unresectable) solid tumor.
- Any cytotoxic chemotherapy from a previous treatment regimen within 14 days.
- Has received prior endocrine therapy as cancer treatment within 2 weeks prior to administration of study intervention.
- Has received palliative radiotherapy encompassing >20% of the bone marrow within 1 week of the first dose of study treatment.
- Has an active infection requiring systemic therapy.
- Has hypertension that cannot be adequately controlled with medication.
- Has active tuberculosis.
- Has active infection such as hepatitis B, hepatitis C
- Has a known history of Human Immunodeficiency Virus (HIV) infection.
15) Impairment of gastrointestinal function or gastrointestinal disorders 16) Is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the screening visit through 6 months after the last dose of the Investigational product.
17) Patients who do not consent to adequate contraception throughout the study period.
18) Has a known hypersensitivity to the components of the investigational product or its analogs.
19) Since this drug contains lactose, patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
20) Since this drug contains Yellow No. 4 (Tartrazine), patients with a history of hypersensitivity or allergy to this ingredient.
21) Medical, psychiatric, cognitive, or other conditions that may interfere with the ability of the subject to understand the subject information, provide the informed consent, follow the protocol process, or complete the clinical trial.
22) The investigator judges that it is not appropriate to participate in this study for else reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Niraparib
|
a highly selective PARP1 and PARP2 inhibitor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
objective response after 8 weeks
Time Frame: at 8 weeks after Cycle 1 Day 1(each cycle is 28 days)
|
Antitumor activity defined as objective response after 8 weeks
|
at 8 weeks after Cycle 1 Day 1(each cycle is 28 days)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GAUSS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Efficacy
-
Brigham and Women's HospitalNational Institutes of Health (NIH); National Institute on Aging (NIA)RecruitingFall Injury | Falls | Exercise Self-Efficacy | Falls Self-EfficacyUnited States
-
Hunan Province Tumor HospitalNot yet recruiting
-
Korea University Anam HospitalActive, not recruiting
-
Beni-Suef UniversityUnknown
-
Ain Shams UniversityCompleted
-
Hospital Universitario Insular Gran CanariaRecruiting
-
Yonsei UniversityRecruiting
-
Jeffrey Eugene, MDAccreditation Council for Graduate Medical EducationNot yet recruiting
-
Alexandria UniversityCompleted
-
Johns Hopkins UniversityCompleted
Clinical Trials on Niraparib
-
Tesaro, Inc.Completed
-
Virginia Commonwealth UniversityGlaxoSmithKline; Puma Biotechnology, Inc.RecruitingOvarian Cancer | Advanced Solid TumorUnited States
-
Tesaro, Inc.Completed
-
Fudan UniversityRecruitingTreatment EfficacyChina
-
Chongqing University Cancer HospitalRecruiting
-
Abramson Cancer Center at Penn MedicineActive, not recruitingProstate AdenocarcinomaUnited States
-
Hunan Cancer HospitalUnknown
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast CancerGermany
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
Lei LiRecruitingChemotherapy | Ovarian Carcinoma | Survival Outcomes | Adverse Events | Niraparib | Anlotinib | CA125 | Targeted Therapy | Recurrent Ovarian CancerChina